All About Multiple Sclerosis

More MS news articles for April 2004

Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15058523

Inflamm Bowel Dis. 2004 Jan;10(1):28-31
Thomas CW Jr, Weinshenker BG, Sandborn WJ.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.

BACKGROUND:

Inflammatory demyelinating disease of the central nervous system may be linked to anti-tumor necrosis factor alpha therapy.

CASE HISTORY:

A 19-year-old female with Crohn's ileocolitis developed right arm and leg numbness and right hand weakness 4 weeks after the initiation of infliximab.

Neurologic examination confirmed upper and lower right extremity sensory and motor deficits.

MRI examination of the head and thoracic cord showed multiple gadolinium-enhancing lesions with distribution and configuration most suggestive of multiple sclerosis or other demyelinating process.

The infliximab therapy was immediately stopped and follow-up at 8 weeks revealed symptomatic improvement.

CONCLUSION:

This case report describes the onset of a demyelinating process after the institution of infliximab therapy in a patient with Crohn's disease.